Workflow
Foghorn Therapeutics(FHTX)
icon
Search documents
Foghorn Therapeutics(FHTX) - 2024 Q2 - Quarterly Results
2024-08-08 11:02
Exhibit 99.1 Foghorn Therapeutics Provides Second Quarter 2024 Financial and Corporate Update Topline Phase 1 dose escalation data for FHD-286 in combination with decitabine, in relapsed and/or refractory AML patients, anticipated in the fourth quarter of 2024 Dosing of first patient in a Phase 1 trial for FHD-909, a potential first-in-class SMARCA2 selective inhibitor, anticipated in the second half of 2024; primary target population in SMARCA4 mutated NSCLC IND-enabling studies for Selective CBP degrader ...
Flagship Pioneering Announces Appointment of Raj Panjabi as Senior Partner
Prnewswire· 2024-08-06 10:30
Former White House Top Health Security Official to Lead Flagship's Preemptive Health and Medicine Initiative CAMBRIDGE, Mass., Aug. 6, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced that globally distinguished healthcare expert, entrepreneur, and public policy leader Raj Panjabi, M.D., MPH, will join Flagship as Senior Partner. Dr. Panjabi will lead Flagship's Preemptive Health and Medicine Initiative (PH&M), which is pioneering a new field to protect, maintain ...
Flagship Pioneering Unveils Abiologics to Pioneer Supranatural Biologics, A New Biotherapeutic Class
Prnewswire· 2024-07-23 10:00
The Abiologics platform leverages cutting-edge generative AI and high throughput chemical protein synthesis to create Synteins™, a new class of programmable medicines that aims to redefine what therapeutics can achieve for patients CAMBRIDGE, Mass., July 23, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today unveiled Abiologics, a company reimagining biologics with the creation of a new class of supranatural and programmable medicines, called Synteins™. Synteins are computat ...
Flagship Pioneering Raises $3.6 Billion to Fuel Breakthrough Innovations that Transform Human Health and Sustainability
Prnewswire· 2024-07-10 10:00
Record Year with Key Partnerships, Global Expansion and Expanded Top Talent "Over the past six years, Flagship has also pioneered AI-enabled platforms that transform drug discovery, speed up the drug development process and gain new insights into human health and sustainability," Afeyan added. "By leveraging the power and potential of generative AI, we're embracing a future in which companies are created and expanded in ways we have not previously experienced, with the prospect for unprecedented impact." Pa ...
Foghorn Therapeutics to Participate in Upcoming Investor Conferences in June
globenewswire.com· 2024-05-28 11:00
CAMBRIDGE, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced management's participation in the Jefferies Global Healthcare Conference and the Goldman Sachs 45th Annual Global Healthcare Conference. With an initial focus in oncology, Foghorn's Gene Traffic Control® platform and resulting broad pipeline have the potentia ...
Foghorn Therapeutics Raises Approximately $110 Million Through Registered Direct Offering to Advance Pipeline
Newsfilter· 2024-05-22 22:21
Positions company to further leverage strength of platform and advance programs through multiple data readouts and clinical value inflection points Strengthens balance sheet with cash, cash equivalents and short-term investments of $310 million and extends cash runway into 2027 CAMBRIDGE, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expressi ...
Foghorn Therapeutics Raises Approximately $110 Million Through Registered Direct Offering to Advance Pipeline
globenewswire.com· 2024-05-22 22:21
Positions company to further leverage strength of platform and advance programs through multiple data readouts and clinical value inflection points Strengthens balance sheet with cash, cash equivalents and short-term investments of $310 million and extends cash runway into 2027 CAMBRIDGE, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expressi ...
Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Misses Revenue Estimates
Zacks Investment Research· 2024-05-06 13:11
Foghorn Therapeutics Inc. (FHTX) came out with a quarterly loss of $0.59 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to loss of $0.73 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -7.27%. A quarter ago, it was expected that this company would post a loss of $0.79 per share when it actually produced a loss of $0.57, delivering a surprise of 27.85%.Over the last four quarters, the company ha ...
Foghorn Therapeutics(FHTX) - 2024 Q1 - Quarterly Report
2024-05-06 11:03
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q _____________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________________ to __________________ Commission File Number: 001-39634 ______________________ Foghorn Therapeutics Inc ...
Foghorn Therapeutics(FHTX) - 2024 Q1 - Quarterly Results
2024-05-06 11:03
Dose escalation in FHD-286 combination trial in AML continues to progress with clinical data expected in the second half of 2024; potential to be a first-in-class oral broad-based dif erentiation therapeutic in AML IND filing submitted for FHD-909, a first-in-class oral BRM (SMARCA2) selective inhibitor; Phase 1 trial planned to begin in the second half of 2024 with primary target population in BRG1 mutated non-small cell lung cancer; first BRM selective inhibitor to enter the clinic IND-enabling studies fo ...